

# Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps

NCT07132827

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 3
<b>Sponsor</b>	Guangdong Hengrui Pharmaceutical Co., Ltd
<b>Enrollment</b>	280 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Weight e40kg
- Diagnosed with chronic rhinosinusitis with nasal polyps (CRSwNP).
- Bilateral nasal polyps at screening and baseline, total NPS e5, e2 points for each nostril.
- NCS e2 at screening and baseline.
- SNOT-22e30 at screening period and baseline.

... and 3 more (see full listing online)

### Exclusion (23)

- Any comorbidities that may affect the efficacy evaluation of nasal polyps.
- Any comorbidities except for asthma that may affect blood EOS levels.
- Concomitant with immunodeficiency.
- Concomitant with contraindications or not suitable for nasal endoscopy.
- Uncontrolled hypertension and/or uncontrolled diabetes.

... and 18 more (see full listing online)

## Locations (1 total)

---

Eye & Ent Hospital of Fudan University, Shanghai, Shanghai Municipality, China